# AstraZeneca clinical trials: 3,505 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 3,505 trials with AstraZeneca as lead sponsor, 273 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by AstraZeneca: 3,505 rows for $115.05, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/astrazeneca

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 3,505
- Recruiting or not yet: 273
- Read on: November 19, 2026

## Trials

The 25 newest of 3,505, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944378 | A Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia | AstraZeneca | Phase 4 | Recruiting | Hyperkalemia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944378) |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| November 13, 2026 | NCT07934420 | An Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Budesonide/Formoterol Fumarate in Participants Aged 4 to Less Than 12 Years... | AstraZeneca | Phase 3 | Not yet recruiting | Asthma | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934420) |
| November 12, 2026 | NCT07933510 | Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate... | AstraZeneca | Observational | Not yet recruiting | Asthma, Uncontrolled Asthma, Asthma-COPD Overlap | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933510) |
| November 12, 2026 | NCT07932496 | A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refractory B-Cell Malignancies. | AstraZeneca | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B-Cell Malignancies | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932496) |
| November 12, 2026 | NCT07930507 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in... | AstraZeneca | Phase 3 | Not yet recruiting | Hypercholesterolemia | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930507) |
| November 6, 2026 | NCT07922330 | A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These... | AstraZeneca | Phase 3 | Not yet recruiting | Obesity, Overweight, Type 2 Diabetes Mellitus | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922330) |
| November 4, 2026 | NCT07916714 | Breast Cancer Real-World Insights and Decision Guidance Evaluation in Hong Kong | AstraZeneca | Observational | Not yet recruiting | Breast Neoplasms | 48,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916714) |
| November 4, 2026 | NCT07914972 | Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC Patients | AstraZeneca | Observational | Not yet recruiting | Non-small Cell Lung Cancer, NSCLC, Stage I-II Unresected NSCLC | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914972) |
| November 4, 2026 | NCT07914881 | A Study to Screen for Lung Cancer in High-risk Individuals Who Have Never Smoked Using Low-dose Computed Tomography (LDCT). | AstraZeneca | Observational | Not yet recruiting | Lung Cancer, Thoracic Tumors | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914881) |
| November 2, 2026 | NCT07911553 | A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to \< 80 Years of Age With Previously Untreated Large B-cell... | AstraZeneca | Phase 3 | Not yet recruiting | Large B-cell Lymphoma | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911553) |
| November 2, 2026 | NCT07911514 | A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 | AstraZeneca | Phase 1 | Not yet recruiting | Healthy Participants | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911514) |
| October 29, 2026 | NCT07905287 | Clarify HPP: Disease Burden of HPP Patients in China | AstraZeneca | Observational | Recruiting | Hypophosphatasia (HPP) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905287) |
| October 22, 2026 | NCT07888517 | Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1)... | AstraZeneca | Observational | Recruiting | Neurofibromatosis Type 1 (NF1) | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888517) |
| October 20, 2026 | NCT07882576 | A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell Lymphoma | AstraZeneca | Observational | Not yet recruiting | Lymphoma, B-Cell | 532 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882576) |
| October 20, 2026 | NCT07882212 | GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study) | AstraZeneca | Observational | Not yet recruiting | Gastric Cancer, Gastroesophageal Junction Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882212) |
| October 16, 2026 | NCT07877818 | A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable... | AstraZeneca | Phase 3 | Recruiting | Gastric, Esophagogastric Junction | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877818) |
| October 15, 2026 | NCT07876817 | A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination... | AstraZeneca | Phase 4 | Not yet recruiting | Muscle-Invasive Bladder Cancer (MIBC) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876817) |
| October 1, 2026 | NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced... | AstraZeneca | Phase 3 | Recruiting | Epithelial Ovarian Cancer | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851025) |
| September 17, 2026 | NCT07824622 | Study of Safety and PK of AZD0543 in Healthy Adults | AstraZeneca | Phase 1 | Recruiting | Human Metapneumovirus Infection | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824622) |
| September 14, 2026 | NCT07816666 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | AstraZeneca | Phase 3 | Recruiting | Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer... | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816666) |
| September 10, 2026 | NCT07812077 | A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of \[14C\]AZD4954 and the Absolute Bioavailability of... | AstraZeneca | Phase 1 | Recruiting | Healthy Participants | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812077) |
| September 2, 2026 | NCT07800754 | A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Everyday Medical Practice | AstraZeneca | Observational | Recruiting | Gastric Cancer, Gastroesophageal Junction Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800754) |
| August 27, 2026 | NCT07790198 | Tezepelumab CRSwNP Real World Study (CREW Study) | AstraZeneca | Observational | Not yet recruiting | Chronic Rhinosinusitis With Nasal Polyps | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790198) |
| August 26, 2026 | NCT07787117 | QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol | AstraZeneca | Observational | Completed | Asthma | 8,681 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07787117) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 11 |
| Phase 1 | 956 |
| Phase 1/2 | 69 |
| Phase 2 | 469 |
| Phase 2/3 | 18 |
| Phase 3 | 797 |
| Phase 4 | 192 |
| Not applicable | 30 |
| Observational | 963 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 2,696 |
| Recruiting | 244 |
| Active not recruiting | 231 |
| Terminated | 225 |
| Withdrawn | 59 |
| Not yet recruiting | 29 |
| Suspended | 7 |
| Approved for marketing | 6 |
| No longer available | 4 |
| Unknown | 3 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 330 |
| Asthma | 313 |
| Pulmonary Disease, Chronic Obstructive | 234 |
| Carcinoma, Non-Small-Cell Lung | 183 |
| Breast Neoplasms | 175 |
| Diabetes Mellitus | 117 |
| Neoplasms | 106 |
| Gastroesophageal Reflux | 86 |
| Schizophrenia | 78 |
| Prostatic Neoplasms | 70 |
| Hypertension | 65 |
| Lung Neoplasms | 61 |
| Hypercholesterolemia | 60 |
| Ovarian Neoplasms | 60 |
| Dyslipidemias | 57 |
| Heart Failure | 55 |
| Neoplasm Metastasis | 53 |
| Renal Insufficiency, Chronic | 50 |
| Obesity | 48 |
| Bipolar Disorder | 47 |
| Lung Diseases | 43 |
| Arthritis, Rheumatoid | 39 |
| Cardiovascular Diseases | 39 |
| COVID-19 | 38 |
| Lupus Erythematosus, Systemic | 34 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Salad bars in the United States](https://specstream.ai/data/businesses/salad-bars/united-states)
- [Urology practices in the United States](https://specstream.ai/data/businesses/urology-practices/united-states)
- [B2B food products companies in the United States](https://specstream.ai/data/businesses/b2b-food-products-companies/united-states)
- [Cleaning companies in the United States](https://specstream.ai/data/businesses/cleaning-companies/united-states)
- [Estate planning law firms in the United States](https://specstream.ai/data/businesses/estate-planning-law-firms/united-states)
- [Hydraulic repair companies in the United States](https://specstream.ai/data/businesses/hydraulic-repair-companies/united-states)
